Table 1 Demographic and clinical characteristics

From: Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study

Characteristic

 

Overall

Age, years (mean (s.d.))

 

35.08 (7.50)

Sex, no. (%)

Female

13 (50.0)

Male

13 (50.0)

Race/ethnicity, no. (%)

Asian/Asian British—Indian

2 (7.7)

Asian/Asian British—Other

3 (11.5)

Black/Black British—African

2 (7.7)

Black/Black British—Caribbean

1 (3.8)

White Irish

2 (7.7)

White Other

4 (15.4)

White UK

12 (46.2)

Employed, no. (%)

Yes

17 (65.4)

No

6 (23.1)

Student

3 (11.5)

BMI, kg per m2 (mean (s.d.))

 

23.85 (2.72)

Age at first MDD onset, years (mean (s.d.))

 

22.65 (8.28)

Duration of current MDD episode, years (median (IQR))

 

3.25 (2.62, 11.75)

Recurrent MDD, no. (%)

Yes

12 (46.2)

No

14 (53.8)

Number of antidepressants trialed, no. (%)

1 to 2

16 (61.5)

3 to 4

6 (23.1)

5 to 6

3 (11.5)

7–10

1 (3.8)

Psychological therapy trialed, no. (%)

Yes

26 (100)

Current antidepressant treatment, no. (%)

Yes

12 (46.2)

No

14 (53.8)

HAM-D at screening (mean (s.d.))

 

21.65 (2.73)

  1. IQR, interquartile range.